Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

By Keller G.A.   Czerniuk P.   Bertuola R.   de Mena F.   Simoni M.V.   Assefi A.R.   Di Girolamo G.  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2203-2211

Informa Healthcare

Access to resources Recommend Favorite

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 5, 2018-03 ,pp. : 1067-1076

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Controlled Comparative Study of Oral Medroxyprogesterone Acetate 1,200 and 600 mg in Patients with Advanced or Recurrent Breast Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 283-290

Karger

Access to resources Recommend Favorite

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT₃ receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee   Morrow Gary   Balu Sanjeev   Craver Chris   Gayle Julie   Cox David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite